Apertura and Atalanta reduce headcount en route toward the clinic

Two cen­tral ner­vous sys­tem dis­or­der biotechs laid off em­ploy­ees re­cent­ly.

New York gene ther­a­py start­up Aper­tu­ra and Boston RNAi biotech Ata­lan­ta Ther­a­peu­tics have trimmed their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.